Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists

Journal of Medicinal Chemistry

Volumn 51, Issue 10, 2008, Pages 2887-2890

  Ward, Simon E ^a   Eddershaw, Peter J ^a,b   Scott, Claire M ^a   Gordon, Laurie J ^a   Lovell, Peter J ^a   Moore, Susan H ^a   Smith, Paul W ^a   Starr, Kathryn R ^a   Thewlis, Kevin M ^a   Watson, Jeannette M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UCB   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; SB 649915; SB 714786; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D ANTAGONIST; SEROTONIN 1D RECEPTOR; SEROTONIN TRANSPORTER;

ARTICLE; BINDING AFFINITY; BIOAVAILABILITY; DEPRESSION; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; NONHUMAN;

ANIMALS; BLOOD-BRAIN BARRIER; CEREBRAL CORTEX; HUMANS; PIPERAZINES; QUINOLINES; RADIOLIGAND ASSAY; RATS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 43949112960     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8001444     Document Type: Article

References (10)

1. Hirschfeld, R. M. History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry 2000, 61, 4-6.
2. de Montigny, C.; Chaput, Y.; Blier, P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. J. Clin. Psychiatry 1990, 51, 4-8.
3. Roberts, C.; Price, G. W.; and Middlemiss, D. N. Ligands for the investigation of 5-HT autoreceptor function. Brain Res. Bull. 2001, 56, 463-469.
4. Ward, S. E.; Harrington, F. P.; Gordon, L. J.; Hopley, S. C.; Scott, C. M.; Watson, J. M. Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J. Med. Chem. 2005, 48, 3478-3480.
5. 1A receptor antagonists and serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 1033-1036.
6. Atkinson, P. J.; Bromidge, S. M.; Duxon, M. S.; Gaster, L. M.; Hadley, M. S.; Hammond, B.; Johnson, C. N.; Middlemiss, D. N.; North, S. E.; Price, G. W.; Rami, H. K.; Riley, G. J.; Scott, C. M.; Shaw, T. E.; Starr, K. R.; Stemp, G.; Thewlis, K. M.; Thomas, D. R.; Thompson, M.; Vong, A. K.; Watson, J. M. 3,4-Dihydro-2H-benzoxazinones are 5-HT(1A) receptor antagonists with potent 5-HT reuptake inhibitory activity. Bioorg. Med. Chem. Lett. 2005, 15, 737-741.
7. 1 receptor ligands. Bioorg. Med. Chem. Lett. 2007, 17, 5214-5217.
8. Watson, J.; Collin, L.; Ho, M.; Riley, G.; Scott, C.; Selkirk, J. V.; Price, G. W. 5-HT(1A) receptor agonist-antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems. Br. J. Pharmacol. 2000, 130, 1108-1114.
9. Stean, T. O.; Atkins, A. R.; Heidbreder, C. A.; Quinn, L. P.; Trail, B. K.; Upton, N. Postsynaptic 5-HT 1B receptors modulate electroshock-induced generalised seizures in rats. Br. J. Pharmacol. 2005, 144, 628-635.
10. All animal work was conducted in compliance with the Home Office guidance on the operation of the Animals (Scientific Procedures) Act 1986.